Milton Weinstein
#61,562
Most Influential Person Now
American health scientist
Milton Weinstein's AcademicInfluence.com Rankings
Milton Weinsteinphilosophy Degrees
Philosophy
#2361
World Rank
#4062
Historical Rank
Logic
#786
World Rank
#1321
Historical Rank
Download Badge
Philosophy
Why Is Milton Weinstein Influential?
(Suggest an Edit or Addition)According to Wikipedia, Milton C. Weinstein is an American health decision scientist and the Henry J. Kaiser Professor of Health Policy and Management at Harvard T.H. Chan School of Public Health. He is also a Professor of Medicine at Harvard Medical School. Publishing over 300 papers in major journals in multiple fields, he is recognized for his current work around affordable healthcare and its improvements. He received four degrees from Harvard University, an AB and MA , MPP 1972Public Policy 1973
Milton Weinstein's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) (1993) (4130)
- Foundations of cost-effectiveness analysis for health and medical practices. (1977) (2110)
- Recommendations of the Panel on Cost-effectiveness in Health and Medicine. (1996) (2059)
- Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. (2014) (1657)
- Clinical Decision Analysis (1980) (1567)
- Performance of a Five-Item Mental Health Screening Test (1991) (1457)
- Five-hundred life-saving interventions and their cost-effectiveness. (1995) (1321)
- The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. (1996) (1236)
- Long-term persistence in use of statin therapy in elderly patients. (2002) (1229)
- Recommendations for Reporting Cost-effectiveness Analyses (1996) (1174)
- Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. (2003) (1155)
- Probabilistic Sensitivity Analysis Using Monte Carlo Simulation (1985) (862)
- Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. (1996) (835)
- The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. (1997) (706)
- Utility Functions for Life Years and Health Status (1980) (698)
- QALYs: the basics. (2009) (659)
- Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. (2004) (577)
- The survival benefits of AIDS treatment in the United States. (2006) (568)
- Expanded screening for HIV in the United States--an analysis of cost-effectiveness. (2005) (565)
- Model Parameter Estimation and Uncertainty Analysis (2012) (549)
- Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. (2012) (543)
- The cost effectiveness of combination antiretroviral therapy for HIV disease. (2001) (499)
- Recommendations of the Panel on Cost-effectiveness in Health and Medicine (1997) (486)
- Does preventive care save money? Health economics and the presidential candidates. (2008) (459)
- The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States (2006) (446)
- The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. (1999) (424)
- Use and misuse of the term "cost effective" in medicine. (1986) (406)
- Economic Burden of Childhood Autism Spectrum Disorders (2012) (402)
- Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. (1987) (393)
- Performance of screening and diagnostic tests. Application of receiver operating characteristic analysis. (1987) (387)
- On the decision rules of cost-effectiveness analysis. (1993) (382)
- Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. (1991) (365)
- Decision Making in Health and Medicine (2001) (353)
- Identifying and Valuing Outcomes (1996) (348)
- Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment (2002) (347)
- Gains in life expectancy from medical interventions--standardizing data on outcomes. (1998) (337)
- Preferences for Health Outcomes (1984) (315)
- Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. (1990) (282)
- Preference-based measures in economic evaluation in health care. (2000) (280)
- Hypertension: A Policy Perspective (1976) (274)
- Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. (2006) (272)
- Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. (2003) (269)
- Comparative effectiveness and health care spending--implications for reform. (2010) (262)
- Critical ratios and efficient allocation (1973) (257)
- Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. (2001) (254)
- The global cost of nonoptimal blood pressure (2009) (253)
- Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness (2001) (251)
- Cost–effectiveness of Coronary Artery Bypass Surgery (1982) (250)
- Allocation of Resources to Manage Hypertension (1977) (248)
- Legislating against use of cost-effectiveness information. (2010) (245)
- HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. (2004) (241)
- Risk reduction for nonmelanoma skin cancer with childhood sunscreen use. (1986) (239)
- Cost-effectiveness of interventions to prevent or treat coronary heart disease. (1985) (239)
- Cost and Health Implications of Cholesterol Lowering (1992) (235)
- Who gets chemotherapy for metastatic lung cancer? (2000) (231)
- The cost-effectiveness of preventing AIDS-related opportunistic infections. (1998) (229)
- A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccine (2003) (229)
- Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis (2006) (228)
- The cost of a successful delivery with in vitro fertilization. (1994) (227)
- Expected Gains in Life Expectancy From Various Coronary Heart Disease Risk Factor Modifications (1991) (224)
- Comparative Effectiveness Evidence From the Spine Patient Outcomes Research Trial: Surgical Versus Nonoperative Care for Spinal Stenosis, Degenerative Spondylolisthesis, and Intervertebral Disc Herniation (2011) (217)
- Expanded HIV Screening in the United States: Effect on Clinical Outcomes, HIV Transmission, and Costs (2006) (216)
- Principles of Cost-Effective Resource Allocation in Health Care organizations (1990) (215)
- Cost-Effectiveness of Computed Tomography Screening for Lung Cancer in the United States (2011) (213)
- Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. (1990) (213)
- Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. (2015) (212)
- Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. (2005) (212)
- Decision making in health and medicine: Integrating evidence and values, second edition (2014) (209)
- Risk Reduction for Nonmelanoma Skin Cancer With Childhood Sunscreen Use (1986) (203)
- Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. (2009) (200)
- The Economic Value of Changing Mortality Probabilities: A Decision-Theoretic Approach (1980) (198)
- Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. (2000) (197)
- Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease. (2001) (196)
- Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. (1988) (195)
- What Do Patients Value?: Willingness to Pay for Ultrasound in Normal Pregnancy (1985) (194)
- A cost-effectiveness analysis of exercise as a health promotion activity. (1988) (192)
- When doctors meet numbers. (1981) (189)
- Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. (1991) (188)
- Recent Developments in Decision-Analytic Modelling for Economic Evaluation (2012) (184)
- Impact of referral patterns on the use of chemotherapy for lung cancer. (2002) (179)
- Cost-effectiveness of a new short-stay unit to "rule out" acute myocardial infarction in low risk patients. (1994) (177)
- Estrogen use in postmenopausal women--costs, risks, and benefits. (1980) (176)
- Outcomes and costs of acute treatment of traumatic brain injury. (2002) (173)
- Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. (1999) (173)
- Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. (1997) (172)
- Medicare and cost-effectiveness analysis. (2005) (165)
- Allocation of subjects in medical experiments. (1974) (164)
- Evaluating the cost-effectiveness of clinical and public health measures. (1998) (164)
- Cost-Effectiveness Analysis of Hypertension Guidelines in South Africa: Absolute Risk Versus Blood Pressure Level (2005) (160)
- When to start antiretroviral therapy in resource-limited settings. (2009) (157)
- A Comparison of Three Psychiatric Screening Tests Using Receiver Operating Characteristic (ROC) Analysis (1989) (157)
- How much are Americans willing to pay for a quality-adjusted life year? (2008) (156)
- Annual financial impact of well‐differentiated thyroid cancer care in the United States (2014) (145)
- Economic Assessments of Medical Practices and Technologies (1981) (144)
- Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group. (1997) (144)
- Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries with Diabetes (2005) (144)
- The Optimal Consumption of Depletable Natural Resources (1975) (143)
- Clinical Outcomes and Costs of Transcatheter as Compared with Surgical Closure of Patent Ductus Arteriosus (1993) (143)
- Cost-effectiveness of a smoking cessation program after myocardial infarction. (1993) (142)
- Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery. (1993) (141)
- Valuing health care: From cost–effectiveness ratios to resource allocation: where to draw the line? (1995) (137)
- Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model. (1994) (134)
- Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. (1996) (133)
- Empirically calibrated model of hepatitis C virus infection in the United States. (2002) (132)
- Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States (2013) (129)
- Pertussis Vaccine: An Analysis of Benefits, Risks, and Costs (1979) (129)
- Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. (2005) (128)
- Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis (2006) (127)
- Cost-effectiveness of routine coronary angiography after acute myocardial infarction. (1996) (126)
- Representing Both First- and Second-order Uncertainties by Monte Carlo Simulation for Groups of Patients (2000) (125)
- The Hepatitis C Cascade of Care: Identifying Priorities to Improve Clinical Outcomes (2014) (122)
- Economic model of a birth cohort screening program for hepatitis C virus (2012) (122)
- Cost-effectiveness of HIV testing and treatment in the United States. (2007) (118)
- Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. (2003) (117)
- Theoretical Foundations of Cost-Effectiveness Analysis (1996) (117)
- The Costs, Clinical Benefits, and Cost-Effectiveness of Screening for Cervical Cancer in HIV-Infected Women (1999) (115)
- Theoretical issues in cost-effectiveness analysis. (1997) (112)
- Comparison of Health State Utilities Using Community and Patient Preference Weights Derived from a Survey of Patients with HIV/AIDS (2002) (112)
- A Note on QALYs, Time Tradeoff, and Discounting (1994) (111)
- Cost-effectiveness of coronary MDCT in the triage of patients with acute chest pain. (2008) (110)
- Coronary Artery Bypass Graft Surgery (1981) (109)
- Uncertainty and Patient Heterogeneity in Medical Decision Models (2010) (107)
- Cost-effectiveness of hormone replacement therapy in the menopause. (1983) (107)
- The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection (2015) (107)
- The cost-effectiveness of air bags by seating position. (1997) (106)
- Health and Economic Benefits of Increased β-Blocker Use Following Myocardial Infarction (2000) (106)
- When does quality-adjusting life-years matter in cost-effectiveness analysis? (2004) (105)
- Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. (2001) (105)
- Guidelines for Pharmacoeconomic Studies (1997) (104)
- Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. (1994) (103)
- Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. (2001) (101)
- The Lifetime Medical Cost Savings From Preventing HIV in the United States (2015) (101)
- A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]. (2018) (100)
- Modeling for health care and other policy decisions: uses, roles, and validity. (2001) (99)
- Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. (2008) (98)
- Should physicians be gatekeepers of medical resources? (2001) (97)
- Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States (2017) (95)
- Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study. (2016) (93)
- Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. (2005) (91)
- Clinical outcomes and cost-effectiveness of coronary computed tomography angiography in the evaluation of patients with chest pain. (2009) (91)
- Population-level changes in folate intake by age, gender, and race/ethnicity after folic acid fortification. (2006) (90)
- Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. (2010) (90)
- Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d’Ivoire: a trial-based analysis (2005) (89)
- A QALY is a QALY is a QALY -- Or is it? (1988) (89)
- Cost-Effectiveness of Motivational Interviewing for Smoking Cessation and Relapse Prevention Among Low-Income Pregnant Women: A Randomized Controlled Trial (2007) (88)
- Limitations of Acceptability Curves for Presenting Uncertainty in Cost-Effectiveness Analysis (2007) (87)
- Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal (2009) (84)
- Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. (2004) (83)
- Cost-effective priorities for cancer prevention. (1983) (82)
- Cost-effectiveness of populationwide educational approaches to reduce serum cholesterol levels. (1997) (81)
- Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. (2008) (81)
- Waiting for Certainty on Covid-19 Antibody Tests - At What Cost? (2020) (80)
- The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization (2020) (79)
- Cost-effectiveness Analysis of Periodontal Disease Control (1987) (78)
- Are Healthy-years Equivalents an Improvement over Quality-adjusted Life Years? (1993) (78)
- Assessing the effectiveness of health interventions for cost-effectiveness analysis (1997) (78)
- Unrelated Donor Bone Marrow Transplantation for Chronic Myelogenous Leukemia: A Decision Analysis (1997) (76)
- The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. (2007) (75)
- The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost. (2001) (74)
- Projected cost-effectiveness of primary angioplasty for acute myocardial infarction. (1997) (74)
- Heart failure disease management programs: a cost-effectiveness analysis. (2008) (72)
- A Comparison of HU12 and HU13 Utility Scores in Alzheimer's Disease (2000) (72)
- Uncertainty in Decision Models Analyzing Cost-Effectiveness (1998) (71)
- Cost‐effectiveness analysis of oxaliplatin compared with 5‐fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US (2007) (70)
- Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. (2001) (69)
- Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. (2004) (69)
- COST-EFFECTIVENESS IMPLICATIONS OF THE TIMING OF ANTIRETROVIRAL THERAPY IN HIV-INFECTED ADULTS (2002) (69)
- Cost-effectiveness of laparoscopic gastric banding and bypass for morbid obesity. (2010) (68)
- Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids (2009) (68)
- Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods. (2006) (67)
- Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. (1993) (67)
- Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. (2013) (65)
- Challenges for Cost-effectiveness Research (1986) (64)
- Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. (2001) (64)
- More americans living longer with cardiovascular disease will increase costs while lowering quality of life. (2013) (61)
- Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy (2007) (60)
- Patients' willingness to pay for autologous blood donation. (1997) (59)
- Projected cost-effectiveness of smoking cessation interventions in patients hospitalized with myocardial infarction. (2011) (59)
- The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. (2007) (59)
- A Comparative Assessment of Non-Laboratory-Based versus Commonly Used Laboratory-Based Cardiovascular Disease Risk Scores in the NHANES III Population (2011) (58)
- Comparative effectiveness: asking the right questions, choosing the right method. (2005) (57)
- The Combined Analysis of Uncertainty and Patient Heterogeneity in Medical Decision Models (2011) (57)
- Use Patterns for Depletable and Recycleable esources2 (1974) (57)
- Cost‐Effectiveness of Hormone Replacement (1990) (57)
- A cost-effectiveness analysis of folic acid fortification policy in the United States (2009) (57)
- Laboratory Monitoring to Guide Switching Antiretroviral Therapy in Resource-Limited Settings: Clinical Benefits and Cost-Effectiveness (2010) (56)
- Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients (2006) (56)
- Patient and community preferences for treatments and health states in multiple sclerosis (2003) (55)
- Cost-Effectiveness of Dual-Chamber Pacing Compared With Ventricular Pacing for Sinus Node Dysfunction (2005) (55)
- The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. (2016) (54)
- Cost-effectiveness of hormone replacement therapy after the menopause. (1991) (54)
- Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy (2001) (53)
- Health and economic benefits of increased beta-blocker use following myocardial infarction. (2000) (52)
- Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis. (2016) (51)
- Cost analysis of "bridging therapy" with low-molecular-weight heparin versus unfractionated heparin during temporary interruption of chronic anticoagulation. (2004) (51)
- Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. (2009) (50)
- Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation. (2014) (50)
- Predicting Mortality after Coronary Artery Bypass Surgery (1998) (50)
- Relative impact of targeted versus populationwide cholesterol interventions on the incidence of coronary heart disease. Projections of the Coronary Heart Disease Policy Model. (1989) (48)
- Elective Hysterectomy: Benefits, Risks, and Costs (1985) (48)
- Clinical Impact and Cost-effectiveness of Diagnosing HIV Infection During Early Infancy in South Africa: Test Timing and Frequency. (2016) (48)
- The Cost Effectiveness of Gonorrhea Screening in Urban Emergency Departments (2005) (47)
- Cost-Effectiveness of Hepatic Metastasectomy in Patients With Metastatic Colorectal Carcinoma: A State-Transition Monte Carlo Decision Analysis (2003) (47)
- Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis. (2008) (46)
- Oregon's Medicaid Ranking and Cost- Effectiveness (1996) (46)
- Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. (2002) (46)
- Using health-related quality-of-life information (1994) (45)
- Can We Better Prioritize Resources for Cost-Utility Research? (2005) (45)
- High-Priced Technology Can Be Good Value for Money (1999) (44)
- The projected health benefits of maternal group B streptococcal vaccination in the era of chemoprophylaxis. (2005) (44)
- The FDA's regulation of health economic information. (2000) (43)
- Cost—Effectiveness of Regulations against Using a Cellular Telephone while Driving (1999) (42)
- The Relationship between Risk Attitude and Treatment Choice in Patients with Relapsing-Remitting Multiple Sclerosis (2002) (42)
- Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States (2017) (41)
- The impact of risk information on patients' willingness to pay for autologous blood donation. (1998) (41)
- Cost-effectiveness analysis of predischarge monitoring for apnea of prematurity. (2003) (40)
- Barriers to using cost-effectiveness analysis in managed care decision making. (2000) (40)
- Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC) (2013) (40)
- Optimal Allocation of Testing Dollars: The Example of HIV Counseling, Testing, and Referral (2005) (40)
- Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection. (2004) (40)
- The Decision Concerning Coronary Angiography in Patients with Chest Pain (1985) (39)
- Health and the War on Poverty: A Ten-Year Appraisal (1980) (39)
- Life Expectancy Biases in Clinical Decision Modeling (1995) (39)
- TREATMENT FOR PRIMARY HIV INFECTION: PROJECTING OUTCOMES OF IMMEDIATE, INTERRUPTED, OR DELAYED THERAPY (2002) (39)
- Chapter 9: The MGH‐HMS Lung Cancer Policy Model: Tobacco Control Versus Screening (2012) (39)
- Adoption and spread of new imaging technology: a case study. (2009) (39)
- The cost-effectiveness of elective Cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy (2000) (38)
- Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study (2009) (38)
- The Anticipated Clinical and Economic Effects of 909090 in South Africa (2016) (38)
- Expert panel vs decision-analysis recommendations for postdischarge coronary angiography after myocardial infarction. (1999) (38)
- Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients (2015) (38)
- Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites. (2006) (37)
- Cost-Effectiveness of Enfuvirtide in Treatment-Experienced Patients With Advanced HIV Disease (2005) (37)
- A QALY is a QALY--or is it? (1988) (37)
- Packaging Health Services When Resources Are Limited: The Example of a Cervical Cancer Screening Visit (2006) (36)
- Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity (2008) (36)
- What is the dentist's occupational risk of becoming infected with hepatitis B or the human immunodeficiency virus? (1992) (36)
- Long-term impact of smoking cessation on the incidence of coronary heart disease. (1990) (35)
- Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial (2012) (35)
- ROC curve regression analysis: the use of ordinal regression models for diagnostic test assessment. (1994) (34)
- The clinical role and cost-effectiveness of long-acting antiretroviral therapy. (2015) (34)
- Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. (2001) (32)
- The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelines. (1999) (32)
- Forum: Use and misuse of the term "cost-effective". (1986) (32)
- Should the Arteriovenous Fistula Be Created before Starting Dialysis?: A Decision Analytic Approach (2011) (32)
- Measuring the costs of outreach motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women (2009) (32)
- Clinical Impact, Costs, and Cost-effectiveness of Expanded Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Massachusetts (2020) (31)
- Clinical outcomes and costs of transcatheter as compared with surgical closure of patent ductus arteriosus. The Patient Ductus Arteriosus Closure Comparative Study Group. (1993) (31)
- Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age (2015) (31)
- Do drug formulary policies reflect evidence of value? (2006) (31)
- Heterogeneity in the relationship between the time tradeoff and Short Form-36 for HIV-infected and primary care patients. (1998) (31)
- Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. (2007) (31)
- Taking account of future technology in cost effectiveness analysis (2004) (30)
- Validation and Calibration of a Computer Simulation Model of Pediatric HIV Infection (2013) (30)
- Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis. (2003) (30)
- Methods of Model Calibration (2012) (29)
- Who Needs Laboratories and Who Needs Statins?: Comparative and Cost-Effectiveness Analyses of Non–Laboratory-Based, Laboratory-Based, and Staged Primary Cardiovascular Disease Screening Guidelines (2014) (29)
- Clinical Outcomes, Costs, and Cost-effectiveness of Strategies for Adults Experiencing Sheltered Homelessness During the COVID-19 Pandemic (2020) (29)
- HIV drug resistance surveillance for prioritizing treatment in resource-limited settings (2007) (28)
- Estimating General-population Utilities Using One Binary-gamble Question per Respondent (1998) (28)
- Cost-Effectiveness of Tdap Vaccination of Adults Aged ≥65 Years in the Prevention of Pertussis in the US: A Dynamic Model of Disease Transmission (2014) (28)
- Cost-Effectiveness of Screening Strategies for Left Main Coronary Artery Disease in Patients with Stable Angina (1988) (28)
- Issues in the economic evaluation of community water fluoridation. (1989) (27)
- Methodologic issues in policy modeling for cardiovascular disease. (1989) (27)
- Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. (2007) (27)
- Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension. (1977) (27)
- A Monte Carlo Simulation of Advanced HIV Disease (1998) (26)
- Incorporating Calibrated Model Parameters into Sensitivity Analyses (2012) (25)
- Clinical Impact, Costs, and Cost-Effectiveness of Expanded SARS-CoV-2 Testing in Massachusetts (2020) (25)
- Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin’s lymphoma: cost-effectiveness analyses (2014) (25)
- Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic (2010) (25)
- Optimal Resource Allocation in Community Hypertension Programs (1978) (24)
- DAILY COST PREDICTION MODEL IN NEONATAL INTENSIVE CARE (2003) (24)
- Sustainable Development in Surgery: The Health, Poverty, and Equity Impacts of Charitable Surgery in Uganda (2016) (23)
- Optimal Frequency of Cd4 Cell Count and HIV Rna Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-Infected Patients (2005) (23)
- A therapeutic HIV vaccine: how good is good enough? (2004) (23)
- The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients (2014) (23)
- Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma (2016) (22)
- Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US (2010) (22)
- BAYESIAN VALUE-OF-INFORMATION ANALYSIS (2001) (22)
- Decision and Cost-Utility Analyses of Surgical versus Transcatheter Closure of Patent Ductus Arteriosus (1998) (22)
- Time Preference in Medical Economics (1994) (21)
- Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. (2019) (21)
- HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy? (2014) (20)
- The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States (2017) (20)
- Methods of cost-effectiveness analysis in the assessment of new drugs for Alzheimer's disease. (1997) (20)
- Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire. (2006) (18)
- Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid (2017) (18)
- Decision Rules for Incremental Cost-effectiveness Analysis (2012) (18)
- Risky Choices in Medical Decision Making: A Survey (1986) (18)
- Spending Health Care Dollars Wisely: Can Cost-Effectiveness Analysis Help? (2005) (18)
- ECONOMIC CONSIDERATIONS IN THE MANAGEMENT OF MILD HYPERTENSION (1978) (18)
- Association Between Medicare Expenditure Growth and Mortality Rates in Patients With Acute Myocardial Infarction: A Comparison From 1999 Through 2014 (2017) (18)
- Retrospective economic evaluation of a controlled trial of indomethacin prophylaxis for patent ductus arteriosus in premature infants. (2006) (17)
- Estrogen use and postmenopausal women: a National Institutes of Health Consensus Development Conference. (1979) (17)
- Understanding the value of minimally invasive procedures for the treatment of lumbar spinal stenosis: the case of interspinous spacer devices. (2017) (17)
- Cost-Effectiveness Analysis of Tdap in the Prevention of Pertussis in the Elderly (2013) (17)
- The costs of prevention (1990) (17)
- Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves (2017) (17)
- Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States (2013) (16)
- Time-preference Studies in the Health Care Context (1993) (16)
- A Structural Comparison of Analytical Models for University Planning. (1970) (16)
- Clinical impact and cost-effectiveness of genotype testing at HIV diagnosis in the United States. (2020) (15)
- Estimation of Mortality Rates for Disease Simulation Models Using Bayesian Evidence Synthesis (2006) (15)
- The Topology of Pareto-Optimal Regions with Public Goods (1974) (15)
- MO2 INCORPORATING CALIBRATED MODEL PARAMETERS INTO SENSITIVITY ANALYSES: DETERMINISTIC AND PROBABILISTIC APPROACHES (2008) (15)
- THE COST-EFFECTIVENESS OF PROPHYLAXIS FOR MYCOBACTERIUM AVIUM COMPLEX IN AIDS (1999) (14)
- Trading Bankruptcy for Health: A Discrete-Choice Experiment. (2018) (14)
- Cost-effective choice of antimicrobial therapy for serious infections (1986) (14)
- Is Less More? A Microsimulation Model Comparing Cost-effectiveness of the Revised American Thyroid Association's 2015 to 2009 Guidelines for the Management of Patients With Thyroid Nodules and Differentiated Thyroid Cancer. (2020) (14)
- Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1 (2016) (14)
- Assessing the Performance of a Computer-Based Policy Model of HIV and AIDS (2010) (13)
- Aflibercept vs. Ranibizumab: cost‐effectiveness of treatment for wet age‐related macular degeneration in Sweden (2016) (13)
- International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework. (2016) (13)
- Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. (2014) (12)
- The Cost of Successful Delivery With In Vitro Fertilization (1995) (11)
- The cost-effectiveness of orphan drugs. (1991) (11)
- Cost effectiveness of a gene expression score and myocardial perfusion imaging for diagnosis of coronary artery disease. (2012) (11)
- Cost Effectiveness of Targeted High-dose Atorvastatin Therapy Following Genotype Testing in Patients with Acute Coronary Syndrome (2013) (11)
- Application of decision analysis to drug selection for formulary addition. (1987) (10)
- Allocating resources: the case of hypertension. (1977) (10)
- Cost-Effectiveness Study of the Extracorporeal Shock-Wave Lithotriptor (1990) (10)
- Erratum: Expected gains in life expectancy from various coronary heart disease risk factor modifications (Circulation 1991;83:1194-1201) (1991) (10)
- Calibrating longitudinal models to cross-sectional data: the effect of temporal changes in health practices. (2011) (10)
- Prevention that pays for itself. (1978) (10)
- Effects of Categorizing Continuous Variables in Decision-Analytic Models (2009) (10)
- Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. (2012) (10)
- Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia (2010) (9)
- The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom (2021) (9)
- Optimal Strategies for the Diagnosis and Treatment of Coronary Artery Disease (1983) (9)
- Cost-effectiveness of Financial Incentives for Patients and Physicians to Manage Low-Density Lipoprotein Cholesterol Levels (2018) (8)
- Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa (2019) (8)
- Cost-effectiveness analysis for clinical procedures in oncology. (1980) (8)
- Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion. (2015) (8)
- Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives (2020) (8)
- Whose Blood Is Safer? (1997) (8)
- Parent Preferences for Health Outcomes Associated with Autism Spectrum Disorders (2019) (8)
- Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data (2012) (7)
- Perspectives on Healthy-years Equivalents (1996) (7)
- Cost-effectiveness of frequent HIV screening among high-risk young men who have sex with men in the United States. (2020) (7)
- Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa (2017) (6)
- Will disease prevention spare the medical commons? (1985) (6)
- Medical management of gallstones (1990) (6)
- Novel microsimulation model of tobacco use behaviours and outcomes: calibration and validation in a US population (2020) (6)
- PIN37 A COMPREHENSIVE NATURAL HISTORY MODEL OF HUMAN PAPILLOMAVIRUS (HPV) INFECTION AND CERVICAL CANCER: POTENTIAL IMPACT OF AN HPV 16/18 VACCINE (2002) (6)
- Developing and Validating Metamodels of a Microsimulation Model of Infant HIV Testing and Screening Strategies Used in a Decision Support Tool for Health Policy Makers (2020) (6)
- MC1 METHODS OF MODEL CALIBRATION:A COMPARATIVE APPROACH (2007) (6)
- Microsimulation or Cohort Modelling? A Comparative Case Study in HIV Infection (2007) (6)
- Toward Alignment in the Reporting of Economic Evaluations of Diagnostic Tests and Biomarkers: The AGREEDT Checklist (2018) (6)
- • Theoretically Correct Cost-Effectiveness Analysis (1999) (6)
- Toward Evaluating the Cost-Effectiveness of Medical and Social Experiments (1985) (5)
- The Optimal Consumption of Depletable Natural Resources: An Elaboration, Correction, and Extension (1978) (5)
- Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models (2017) (5)
- The Impact of the 2013 WHO Antiretroviral Therapy Guidelines on the Feasibility of HIV Population Prevention Trials (2014) (5)
- Screening for hypertension (1978) (5)
- Budget Impact of Medicaid Section 1115 Demonstrations for Early HIV Treatment (2005) (5)
- Decision Making in Health and Medicine: Valuing outcomes (2014) (5)
- Management Strategies for People Experiencing Sheltered Homelessness during the COVID-19 Pandemic: Clinical Outcomes and Costs (2020) (5)
- Clinical impact and cost-effectiveness of early infant HIV diagnosis in South Africa : Test timing and frequency (2016) (5)
- The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom (2021) (5)
- Optimizing infant HIV diagnosis with additional screening at immunization clinics in three sub‐Saharan African settings: a cost‐effectiveness analysis (2021) (4)
- Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US (2015) (4)
- Cardiovascular disease prevention with a multidrug regimen in the developing world : a cost-eff ectiveness analysis (2006) (4)
- Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability (2012) (4)
- WW5: CREATIVE APPROACHES TO MODELING LIFE EXPECTANCY GAINS FOR ECONOMIC EVALUATION USING PUBLISHED DATA (2001) (4)
- Cost-Effectiveness of Posaconazole vs Fluconazole in the Prevention of Invasive Fungal Infections among Patients with Graft-Versus-Host Disease (GVHD) in the US. (2007) (3)
- Quantitative Risk Stratification in Markov Chains with Limiting Conditional Distributions (2009) (3)
- Coronary artery bypass surgery is still cost-effective: using calibrated models toupdate clinical trials (2003) (3)
- Economic Impact and Cost-Effectiveness of Medical Technology (1983) (3)
- Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in the U.S (2005) (3)
- Heterogeneity and uncertainty (2014) (3)
- Cost-effectiveness analysis of BOOSTRIX® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) among Individuals≥ 65 years of age in prevention of Pertussis (2012) (3)
- Presidential Reflections on the 25th Anniversary of the Society for Medical Decision Making (2004) (3)
- PMH26: COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN ACUTE BIPOLAR MANIA (2003) (3)
- Sequential Value-of-Information Assessment for Prospective Drug Safety Monitoring Using Claims Databases (2013) (3)
- Sample-size estimation: a sensitivity analysis in the context of a clinical trial for treatment of mild hypertension. (1979) (3)
- Practices Task Force Working Group Model Parameter Estimation and Uncertainty Analysis : A Report of the ISPOR-SMDM Modeling Good (2012) (3)
- Cost-Effectiveness of Primary Prophylaxis With Pegfilgrastim Vs Lipegfilgrastim To Reduce The Incidence of Febrile Neutropenia In Patients With Early Stage Breast Cancer or Non-Hodgkin Lymphoma (2015) (3)
- A Report of the ISPOR Health Science Committee – Task Force on Good Research Practices – Modeling Studies (2003) (3)
- Decision Making in Health and Medicine: Choosing the best treatment (2014) (2)
- TR4 PUBLIC HEALTH AND ECONOMIC IMPACT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN AN INFLUENZA PANDEMIC IN SINGAPORE AND HONG KONG (2010) (2)
- PHP26 COST-EFFECTIVENESS OF SCREENING DONATED BLOOD WITH MINIPOOL NUCLEIC ACID TESTING (NAT) FOR HEPATITIS B VIRUS (HBV), HEPATITIS C VIRUS (HCV), AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) (2002) (2)
- Quality-adjusted life years: application to food safety priority setting. (2005) (2)
- Modeling Adherence Interventions Among Youth with HIV in the United States: Clinical and Economic Projections (2021) (2)
- Cost-Effectiveness of Posaconazole Versus Standard Azole Therapy in the Prevention of Invasive Fungal Infections among High-Risk Neutropenic Patients in the U.S. (2006) (2)
- Decision Making in Health and Medicine: Elements of decision making in health care (2014) (2)
- Monitoring of antiretroviral therapy in low-resource settings (2008) (2)
- Coronary artery bypass surgery is still cost-effective: using calibrated models to update clinical trials. (2003) (2)
- COST-EFFECTIVENESS ANALYSES OF STATISTICALLY INEFFECTIVE TREATMENTS. AUTHORS' REPLY (1998) (2)
- Uncovering psychiatric test information with graphical techniques of exploratory data analysis (1991) (2)
- A Budget Impact Model Of The Addition Of Telotristat Ethyl Treatment In Patients With Uncontrolled Carcinoid Syndrome (2017) (2)
- Cancer prevention: setting priorities. (1983) (2)
- Adjuvant Ovarian Suppression Versus Chemotherapy for Premenopausal, Hormone-responsive Breast Cancer: Quality of Life and Efficacy Tradeoffs (2005) (2)
- PCN72 THE IMPACT OF INITIAL TREATMENT CHOICE AND DISEASE PROGRESSION ON THE ECONOMIC BURDEN OF PATIENTS AND THEIR CAREGIVERS—A LONGITUDINAL STUDY OF STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC) (2008) (2)
- PCN162 EXTRAPOLATION IN TRIAL-BASED COST-EFFECTIVENESS MODELING: IN SEARCH OF A STANDARD (2010) (2)
- A novel method to estimate the indirect community benefit of HIV interventions using a microsimulation model of HIV disease (2020) (2)
- A decision analysis comparing 3 active surveillance protocols for the treatment of patients with low‐risk prostate cancer (2019) (2)
- PIN28 USE OF PEGINTERFERON ALFA-2B IN CHRONIC HEPATITIS C PATIENTS FAILING PRIOR THERAPY: A COSTEFFECTIVENESS ANALYSIS (2008) (2)
- Psychological Considerations in Valuing Health Risk Reductions (2019) (2)
- PCV14 COST-EFFECTIVENESS OF THROMBOPROPHYLAXIS IN ACUTELY-ILL MEDICAL INPATIENTS (2002) (1)
- PCV22 HEALTH AND ECONOMIC BURDEN OF POOR MEDICATION ADHERENCE IN THE UNITED STATES (2005) (1)
- Canadian Economic Analysis of Bevacizumab, Cetuximab, and Panitumumab in the First Line Treatment of Kras Wild-Type Metastatic Colorectal Cancer (MCRC) (2012) (1)
- Clinical Outcomes, Costs, and Cost-effectiveness of Strategies for People Experiencing Sheltered Homelessness During the COVID-19 Pandemic (2020) (1)
- Track E Implementation Science, Health Systems and Economics (2012) (1)
- PCN131 REPRESENTING UNCERTAINTY IN CALIBRATED CANCER TREATMENT MODELS: A PRACTICAL APPROACH (2011) (1)
- sounding board Medicare and Cost-Effectiveness Analysis (2005) (1)
- Reporting Cost-effectiveness Analyses With Confidence-Reply (1997) (1)
- Issues in Risk Assessment and Analysis for the Chlorofluorocarbon Problem (1982) (1)
- Out-of-pocket costs (OPC) and time costs (TC) for patients with stage IV non-small cell lung cancer (NSCLC) and their caregivers. (2004) (1)
- 4. Obstacles to Controlling Hypertension (1976) (1)
- An Economic Comparison of Influenza Vaccines Recommended for Use in Eligible Adults under 65 Years in the United Kingdom (2022) (1)
- PNP34: PATIENT PREFERENCE-BASED TREATMENT RECOMMENDATIONS FOR ENDOMETRIOSIS PAIN: CHOICE OF METHOD MATTERS (2003) (1)
- PCN38 ECONOMIC ANALYSIS OF COLORECTAL CANCER SCREENING FROM MULTIPLE STAKEHOLDER PERSPECTIVES: KEY COMPONENTS TO IMPROVE PRACTICAL APPLICATIONS IN THE US (2019) (1)
- Cost-effectiveness of Statin Therapy for ASCVD--Reply. (2015) (1)
- Modeling dental health care workers' risk of occupational infection from bloodborne pathogens. (1990) (1)
- Decision Making in Health and Medicine: Multiple test results (2014) (1)
- CV1 NONCOMPLIANCE WITH STATIN THERAPY: LOST CLINICAL BENEFITS AND IMPLICATIONS FOR COST-EFFECTIVENESS (2002) (1)
- Decision Making: DISCUSSION AGENDA FOR THE SESSION ON MEDICAL DECISION MAKING and MINUTES OF A GROUP DISCUSSION ON CLINICAL DECISION MAKING (1988) (1)
- Cost effectiveness of automated multichannel chemistry analyzers (1981) (1)
- Cost-Effectiveness Analyses (2001) (1)
- Economic Techniques for Technology Assessment (1988) (1)
- CS2 COST-EFFECTIVENESS OF COMPETING ANTIPSYCHOTIC MONOTHERAPIES IN ACUTE BIPOLAR MANIA IN THE U.K. (2004) (1)
- Cost-Effectiveness Of Prophylaxis Treatment Strategies For Febrile Neutropenia In Recurrent Ovarian Cancer Patients (2013) (1)
- Benefits and risks of pertussis vaccine: further comments. (1980) (1)
- Track C Epidemiology and Prevention Science (2012) (1)
- Prevention of cardiovascular disease with a polypill – Authors' reply (2007) (0)
- PNL17 ECONOMIC COSTS OF CHRONIC PRIMARY INSOMNIA IN THE UNITED STATES (2006) (0)
- Closing Remarks (1987) (0)
- Health and Economic Benefits of Increased (cid:98) -Blocker Use Following Myocardial Infarction (2000) (0)
- Case 4-2008: A Pregnant Woman with a Swollen Left Breast and Dyspnea (2008) (0)
- PCV51 A FLEXIBLE TOOL TO ESTIMATE MEDICAL-CARE COSTS FOR STUDY EVENTS IN CARDIOVASCULAR ENDPOINTTRIALS (2008) (0)
- Cost-Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure in the US (2008) (0)
- Factors Contributing to Declines in Cardiac Mortality-Reply (1997) (0)
- Cost-Effectiveness Of Posaconazole Versus Fluconazole/ Itraconazole In The Prevention Of Invasive Fungal Infections Among High-Risk Neutropenic Patients In Singapore (2013) (0)
- The cost-effectiveness of a resilience-based psychosocial intervention for HIV prevention among MSM in India (2022) (0)
- Decision Making in Health and Medicine: Recurring events (2014) (0)
- Cost-Effectiveness of Intravitreal Aflibercept in Treating Neovascular Age-Related Macular Degeneration in Sweden (2013) (0)
- PHP42 METHODS FOR “GO/NO-GO” MODELING OF COMPOUNDS IN THE DEVELOPMENT PIPELINE (2004) (0)
- Symbol-oriented failure analysis in multicomponent systems (1969) (0)
- TAKEMI PROGRAM IN INTERNATIONAL HEALTH Harvard School of Public Health THE CASE OF HYPERTENSIVE CARE An empirical test of drug expenditure model (2004) (0)
- PCN10 COST-EFFECTIVENESS OF BREAST CANCER RISK ASSESSMENT IN PRIMARY CARE (2007) (0)
- BI1 ANALYZING OVERALL SURVIVAL IN RANDOMIZED CONTROLLED TRIALS WITH CROSS-OVER (2010) (0)
- Cost-effectiveness analysis of post-ischaemic heart disease patients in developing regions of the world (2005) (0)
- Decision Making in Health and Medicine: Constrained resources (2014) (0)
- Screening for HIV in general population not cost-effective. (2005) (0)
- Session II: Clinical decision making: Clinical problems; How to teach problem solving strategies (1986) (0)
- The Cost-effectiveness of Antihypertensive Drugs-Reply (1990) (0)
- Appendix to Chapter 2 (1976) (0)
- MEMORIAL TRIBUTE TO JANE C. WEEKS, M.D., M.SC. (2013) (0)
- IN4 COST-EFFECTIVENESS OF DORIPENEM INTHETREATMENT OF NOSOCOMIAL PNEUMONIA (2008) (0)
- Versus Blood Pressure Level Cost-Effectiveness Analysis of Hypertension Guidelines in South Africa : Absolute Risk (2005) (0)
- PID6: HIV/AIDS HEALTH STATE UTILITIES USING COMMUNITY AND PATIENT PREFERENCE WEIGHTS: WHEN DOES IT MATTER? (2001) (0)
- PMD21 IS CYBERKNIFE A COST-EFFECTIVE OPTION FOR TREATING PROSTATE CANCER? (2011) (0)
- 116. Potential Clinical Impact of Respiratory Syncytial Virus (RSV) Vaccination in Older Adults in the United States (2022) (0)
- 8. Findings and Recommendations (1976) (0)
- PMS6 ESTIMATED CLINICAL & ECONOMIC IMPACT OF POOR PATIENT PERSISTENCE WITH OSTEOPOROSIS MEDICATIONS IN BRASIL (2009) (0)
- Cost-Effectiveness Analysis of Arsenic Trioxide for The Treatment of In Patients With Acute Promyelocytic Leukemia (2015) (0)
- 9: Decreasing length of stay for vaginal hysterectomy through quality improvement cycle (2016) (0)
- 5. Detecting Hypertension (1976) (0)
- Letter to the Editor (1988) (0)
- Abstract 15562: Cost-Effectiveness of STEMI Management Strategies for Patients Presenting to Non-Urban Centers: A Model-Based Analysis (2013) (0)
- Appendix to Chapter 7 (1976) (0)
- Cost-effectiveness analyses [3] (multiple letters) (2001) (0)
- 901-66 Vitamin E for Coronary Heart Disease: What is at Stake? (1995) (0)
- The potential clinical impact of implementing different COVID-19 boosters in fall 2022 in the United States (2022) (0)
- FACTORS CONTRIBUTING TO DECLINES IN CARDIAC MORTALITY. AUTHORS' REPLY (1997) (0)
- Public And Private Payer Perspectives On The Net Cost Of Implementation Of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Compared With 7-Valent Pneumococcal Conjugate Vaccine (PCV7) To In The United States (2014) (0)
- Track B Clinical Science (2012) (0)
- PHP31 OUTCOMES AND COSTS OF ACUTE TREATMENT OF TRAUMATIC BRAIN INJURY (2002) (0)
- 90352100 Cost effectiveness of screening perimenopausal white women for osteoporosis: Bone densitometry and hormone replacement therapy (1991) (0)
- Letter to the Editor (2003) (0)
- Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma you. Your story matters (2016) (0)
- OP1 IS THE CURRENT METHOD OF VALUING HEALTH OUTCOMES IN COST-EFFECTIVENESS ANALYSIS VALID? (2004) (0)
- TUPDC0103: Gonorrhea infections diagnosed among persons living with HIV: cross matching surveillance registries to identify potential opportunities for integrated partner services-New York City, Washington D.C., Miami/Dade County and Arizona (2012) (0)
- Decision Making in Health and Medicine: Finding and summarizing the evidence (2014) (0)
- Decision Making in Health and Medicine: Psychology of judgment and choice (2014) (0)
- Allocation of subjects in medical experiments. 1974. (1995) (0)
- While Lowering Quality Of Life More Americans Living Longer With Cardiovascular Disease Will Increase Costs (2013) (0)
- PCV28 A COST ANALYSIS OF “BRIDGING THERAPY” FOR PATIENTS REQUIRING INTERRUPTION OF CHRONIC ANTICOAGULATION (2002) (0)
- Cancer prevention: setting priorities. (1983) (0)
- In Memoriam (2014) (0)
- PCN148 BUDGET IMPACT OF IMPROVING ADHERENCE TO COLORECTAL CANCER SCREENING (2020) (0)
- Decision Making in Health and Medicine: Estimation, calibration, and validation (2014) (0)
- PIH7 COST-EFFECTIVENESS OF MAGNETIC RESONANCE IMAGE-GUIDED FOCUSED ULTRASOUND (MRGFUS) FOR THE TREATMENT OF UTERINE FIBROIDS (2007) (0)
- The Impact of Birth-Cohort Screening for Hepatitis C Virus (HCV) Compared With Current Risk-Based Screening on Lifetime Incidence of and Mortality From Advanced Liver Disease (AdvLD) in the United States (U.S.) (2011) (0)
- Do Utility Values Reflect Lost Income And The Full Opportunity Cost Of Work Loss (2014) (0)
- 7. Evaluation of Specific Causes of Hypertension: Cost- Effectiveness Considerations (1976) (0)
- The Harvard-MIT-NEMC Research Training Program in Medical Informatics (1994) (0)
- Decision Making in Health and Medicine: Deciding when to test (2014) (0)
- Decision Making in Health and Medicine: Interpreting diagnostic information (2014) (0)
- Book Reviews : Methods for the Economic Evaluation of Health Care Programmes. By MICHAEL F. DRUMMOXD, GREG L. STODDART, AND GEORGE W. TORRANCE. Oxford, Oacford University Press, 1987. 182 pages (1988) (0)
- Reply to Kaplan: Coronary Heart Disease Policy Model. (1992) (0)
- 2. Cost-Effectiveness of Treatment (1976) (0)
- RS2 COST-EFFECTIVENESS OFTELITHROMYCIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA (2006) (0)
- PCN145 THE IMPACT OF INCREASING MT-SDNA USE AMONG COLORECTAL CANCER SCREENERS IN A US EMPLOYER POPULATION (2020) (0)
- HP2 IS IT COST-EFFECTIVE TO IMPROVE COMPLIANCE WITH LIPID-LOWERING THERAPY? (2002) (0)
- Neoadjuvant versus upfront surgical strategies in patients with resectable pancreatic adenocarcinoma: A decision analysis. (2010) (0)
- The health economic impact of varying levels of adherence to colorectal screening on providers and payers (2021) (0)
- HR1 DO DRUG PRICES REFLECT VALUE? DO FORMULARY POLICIES? (2004) (0)
- Cost‐effectiveness of broadly neutralizing antibody prophylaxis for HIV‐exposed infants in sub‐Saharan African settings (2023) (0)
- REPORTING COST-EFFECTIVENESS ANALYSES WITH CONFIDENCE. AUTHORS' REPLY (1997) (0)
- A Model of HIV Patient Care: Methods and Applications to the Cost-Effectiveness of Anti-Viral Therapy (2000) (0)
- PSY7 THE BUDGETARY IMPACT OF INCLUDING LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING AS A COVERED SURGICAL TREATMENT FOR MORBIDLY OBESE ADULTS IN A MANAGED CARE POPULATION (2008) (0)
- PIH22 EVALUATING THE COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING AND HUMAN PAPILLOMAVIRUS VACCINATION STRATEGIES USING A MATHEMATICAL MODEL (2010) (0)
- PSY23 COST-EFFECTIVENESS OF LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING AND LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS IN THE TREATMENT OF MORBID OBESITY (2008) (0)
- MC7 THE PHARMACOGENOMICS BIAS IN DECISION MODELS (2005) (0)
- PRS14 RISK-BENEFIT ASSESSMENT OF TELITHROMYCIN FOR THE TREATMENT OF CAP USING QUALITY-ADJUSTED DAYS (QAD) LOST (2005) (0)
- vii Foreword ix Preface xi Acknowledgments xiii List of abbreviations xv 1 Elements of decision making in health care 1 2 Managing uncertainty (2003) (0)
- 3. Drug Side Effects and the Cost-Effectiveness of Treatment (1976) (0)
- PIN21 COST-EFFECTIVENESS OF THE ACIP RECOMMENDED ADULT IMMUNIZATION SCHEDULE IN THE US (2010) (0)
- 6. Allocating Resources to Manage Hypertension in a Community (1976) (0)
- PMS4 CHARACTERIZING UNCERTAINTY IN EARLY-DEVELOPMENT BUDGETARY IMPACT MODELS: A CASE STUDY OF DENOSUMAB (2010) (0)
- The impact of increasing multitarget stool DNA use among colorectal cancer screeners in a self-insured US employer population (2021) (0)
- PCN3 POTENTIAL IMPACT OF WANING OF VACCINE-INDUCED IMMUNITY AGAINST HUMAN PAPILLOMAVIRUS 16/18 (2004) (0)
- Impact of breast cancer risk assessment in primary care: Modeling clinical outcomes and effectiveness (2016) (0)
- The Negative Side of Cost-effectiveness Analysis-Reply (1997) (0)
- PIN18 PROJECTED CLINICAL BENEFITS AND COSTEFFECTIVENESS OF AN HPV 16/18 VACCINE (2003) (0)
This paper list is powered by the following services:
Other Resources About Milton Weinstein
What Schools Are Affiliated With Milton Weinstein?
Milton Weinstein is affiliated with the following schools:
